Skip to main content
. 2023 Sep 26;10(3):37–60. doi: 10.15586/jkcvhl.v10i3.295

Table 5:

MiTF-translocation histology.

Agent (trial, year) Phase N per group Primary endpoint ORR, % (95% CI) mPFS, months
(95% CI)
OS, months (95% CI)
Sunitinib vs. everolimus
(ESPEN, 2016)(18)
II 3 Sunitinib
4 Everolimus
PFS NA
NA
6.1 (6.0–8.8)
3.0 (1.3–NA)
16.2 (8.8–NA)
8.1 (5.5–23)
Axitinib (2018)(23) II 7 PFS NA 11.1 (7.6–14.6) 16.9

ORR: overall response rate, mPFS: median progression-free survival, OS: overall survival, NA: not assessed.